中国经济网北京9月1日讯奥锐特（605116）(605116.SH)近日发布了股东减持股份计划公告。因部分合 伙人自身资金需求，自公告发布之日起15个交易日后的3个月内(窗口期不减持)，天台铂融投资合伙企 业(有限合伙)(以下简称"天台铂融")拟通过集中竞价、大宗交易方式减持公司股份不超过2,176,600股， 即不超过公司总股本的0.54%。公司实际控制人不参与本次减持。 截至公告发布日，公司的股份总数为406,195,234股，天台铂融及其一致行动人浙江桐本投资有限公司、 天台铂恩投资管理合伙企业(有限合伙)合计持有公司股份170,096,400股，占公司总股本的41.88%。其中 天台铂融持有公司股份9,907,200股，占公司总股本的2.44%，浙江桐本持有公司股份153,583,200股，占 公司总股本的37.81%，天台铂恩持有公司股份6,606,000股，占公司总股本的1.63%。上述股份均来源于 公司首次公开发行股票前取得的股份。 奥锐特发布的《关于公司2024年度募集资金存放与实际使用情况的专项报告》显示，根据中国证券监督 管理委员会《关于同意奥锐特药业股份有限公司向不特定对象发行可转换公司 ...

Core Viewpoint - The company is experiencing stable growth in traditional business while new sectors are contributing significantly to high growth, particularly in nuclear medicine, cardiovascular precision intervention, pharmaceutical technology, and biotechnology [1] Group 1: Nuclear Medicine Development - The demand for nuclear medicine is increasing due to aging populations and rising cancer incidence, leading to market expansion for diagnostic and therapeutic applications [1] - The core commercial product, Yttrium-90 microspheres, is expected to grow over 140% in 2024, supported by training of over 1,100 doctors across more than 70 hospitals and inclusion in 45 health insurance plans [1] - The company has 12 innovative RDC products in its pipeline, with 4 approved for clinical research and 3 in Phase III trials, including TLX591-CDx for prostate cancer and TLX250-CDx for renal cell carcinoma [1] Group 2: New Product Opportunities - The company has a diverse range of existing products, but the inclusion of Lishuan in the 10th batch of national procurement is expected to exert short-term pressure on performance [2] - New products in sepsis (STC3141) and ophthalmology are anticipated to have significant market potential, with STC3141 projected to reach peak sales of 10 billion yuan based on a 20% market share and a unit price of 8,000 yuan [3] - The company is also advancing in the ENT field with multiple products in development, including a nasal spray expected to be approved by the end of 2024 [3] Group 3: Financial Projections - Revenue projections for 2025-2027 are estimated at 12.203 billion, 13.292 billion, and 14.663 billion HKD, with net profits of 2.076 billion, 2.422 billion, and 2.764 billion HKD respectively, indicating a low valuation compared to peers [4] - The current price-to-earnings (PE) ratios are projected at 15, 13, and 11 times for the respective years, compared to an average of 25, 23, and 20 times for comparable companies, suggesting the company is undervalued [4]